Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
about
Sequential versus combination chemotherapy for advanced colorectal cancerCapecitabine in the management of colorectal cancerThe clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerPhase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Pharmacologic resistance in colorectal cancer: a reviewTherapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesEfficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysisReview of systemic therapies for locally advanced and metastatic rectal cancerManagement of locally advanced and metastatic colon cancer in elderly patientsIncidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsEffect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-AnalysisUnresolved issues and controversies surrounding the management of colorectal cancer liver metastasisDecision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Oral drugs in the treatment of metastatic colorectal cancer.Irinotecan-induced dysarthria.Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsAn individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerA phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review.A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumorsQuality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerColorectal cancer: from prevention to personalized medicine.Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancerOxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapyCapecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancerIncreasing Access to Oral Anticancer Medicines in Middle-Income Countries: A Case Study of Private Health Insurance Coverage in Brazil.A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumorsMaintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinomaA phase I study of an oral simulated FOLFOX with high dose capecitabine.Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
P2860
Q24234461-4D17FB47-5D54-4935-BCAC-2B1B29C150CFQ24633039-DBE32C04-7040-42AB-AF25-ED3A42723682Q24652904-1D889708-2B97-41FD-A897-095D904F8EAEQ25256709-AB5EA7B1-2C52-4064-AC0B-855D6AC0BB8BQ25257445-75394172-B857-41F2-BF63-2B433F8A069DQ26752747-051C7538-AD90-43B7-BC70-BF1FEE9BD1D3Q26769850-6603255B-4FA2-4C6B-ACAC-367DEF15614FQ26777679-0DC87000-630C-4597-9269-A794B2C0F046Q26865057-FFA35060-BF93-4DEF-89C1-B9C6A8B8D6CCQ27021105-3E514B28-ACE5-49F8-BCF5-0AAD8602F755Q27026129-6EF2096C-0347-4EEE-9AA3-0E254E338594Q27028095-F8F42F3D-AA56-4F78-BFF8-C798B5CD2572Q28066866-EACCD81A-35DE-4D0E-B537-006036F375B7Q28085651-A6D39081-1A9E-4643-B083-7DCBD4FF1CE5Q30244769-C4AEDAD6-E2CA-4F1B-AE86-EC41362AD41EQ30251387-0D402DE1-2835-47FC-A6E3-04FF4BBF32A9Q30470164-DB30D461-31B7-4F96-B88B-446AD2104B53Q30913489-1FF46C1D-BA41-4EC3-88D8-566607EB46C1Q31106341-1709919E-71B0-4ADF-866F-763D8BBE1B9AQ33344682-C126372D-4805-49D7-AA6B-7A2B276EDCC7Q33368148-110EF2EE-B106-4FEF-B95C-DA01E5DC1D7AQ33370303-76EADB0A-4C29-4B64-AF33-AC71D224581DQ33370632-CCB7A400-DBF1-4EAA-B527-B0AA083DE49EQ33399530-60B012EA-29CD-48B9-B37F-57348A0482D8Q33426732-907C6261-7F69-4FE2-B0CD-FF0EA52B1F84Q33442681-F8912B4F-09C2-4069-91F5-4C458C3F8ADEQ33455278-B5C76887-BB94-44E8-A37B-12C100E822B6Q33619858-9BDDA8F5-7B5C-4614-9BB5-7ABDAD0FA16DQ33620052-A8932366-DCB9-4B64-88EE-9BDB231179D3Q33735234-C5E5AF42-267F-4095-8B18-DA2E16ABD427Q33746816-E52F4412-DA23-4935-89DE-DE54DE12C647Q33747440-312D5222-40E8-47C0-AFEE-0E59772AA7A5Q33831232-D45DF032-5E07-411A-BA73-1491E272DAD4Q33847848-06BA7B9A-EDE5-4D30-8D8A-E37E537D3990Q33873230-464C656D-32FE-4EAD-A25F-41389DA3AC72Q33919101-52F6FF44-FE6F-4319-A16B-ED7090EF8BE1Q33967458-8AE4AAD9-F406-4783-9CD1-8379A9E9C1CDQ33973344-15667D1A-7F63-4B2E-9CD5-10E65FB454CFQ34006430-A8831C86-3708-453B-A2E8-C6AA00F3E3EDQ34165276-70787EB4-F367-4992-B73C-56C2306E135C
P2860
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Comparison of oral capecitabin ...... a randomized phase III study.
@ast
Comparison of oral capecitabin ...... a randomized phase III study.
@en
Comparison of oral capecitabin ...... a randomized phase III study.
@nl
type
label
Comparison of oral capecitabin ...... a randomized phase III study.
@ast
Comparison of oral capecitabin ...... a randomized phase III study.
@en
Comparison of oral capecitabin ...... a randomized phase III study.
@nl
prefLabel
Comparison of oral capecitabin ...... a randomized phase III study.
@ast
Comparison of oral capecitabin ...... a randomized phase III study.
@en
Comparison of oral capecitabin ...... a randomized phase III study.
@nl
P2093
P1476
Comparison of oral capecitabin ...... a randomized phase III study.
@en
P2093
B Osterwalder
E Harrison
H U Burger
M Kuperminc
P304
P356
10.1200/JCO.2001.19.8.2282
P407
P577
2001-04-01T00:00:00Z